Compare Manulife Financial Corporation (MFC) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Zoetis Inc — how do they compare? Manulife Financial Corporation trades at $42.51 (market cap $69.96B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Manulife Financial Corporation is far larger — about 2.2× Zoetis Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.14%). Which is the better fit depends on your goals.
| MFC | ZTS | |
|---|---|---|
Market Cap | $69.96B | $31.95B |
Sector | Financials | Health |
52-Week High | $43.39 | $156.76 |
52-Week Low | $29.90 | $71.91 |
Enterprise Value | $66.52B | $39.24B |
Dividend Yield | 3.14% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MFC trades at $42.83, down 1.29% today, with a bullish technical signal supported by moving averages. The company reported revenue of $53.01B in 2025 and net income of $5.78B, with a P/E of 17.39. Recent news highlights AI advancements and strong Asia performance, while Q1 2026 earnings missed expectations. Analyst consensus is 57% buy with no sell ratings.
Outlook remains positive driven by AI initiatives and Asia growth, but risks include Q1 earnings miss and regulatory scrutiny. The stock offers steady profitability and dividend income, yet faces headwinds from wealth management outflows and competitive pressures in core markets.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
